Aquestive Therapeutics Announces Completion of FDA Type A Meeting for Anaphylm™; NDA Resubmission Guidance Reaffirmed

Key Points for Investors

• Successful Completion of FDA Type A Meeting: Aquestive Therapeutics, Inc. announced it has completed an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, intended for the treatment of Type 1 allergic reactions, including anaphylaxis.
• Preliminary FDA Comments Received: The company received preliminary feedback from the FDA on the pharmacokinetic (PK) and human factors (HF) study designs, which are critical components for the NDA resubmission.
• Guidance to Resubmit NDA in Q3 2026 Reaffirmed: Based on the outcome of the Type A meeting, Aquestive has reaffirmed its guidance to resubmit the Anaphylm NDA in the third quarter of 2026.
• Final FDA Meeting Minutes Expected Early May 2026: The company expects to receive the final meeting minutes from the FDA by early May 2026, which will further clarify and finalize the regulatory pathway.
• FDA Alignment on Critical Program Elements: The FDA confirmed the company’s approach on several key elements, including the PK study design, labeling language for potential chewing of the film (avoiding additional clinical data), and recommended changes to user groups in the HF study.
• Product Packaging Improvements: Aquestive shared revisions to the opening mechanism of Anaphylm’s container closure, aiming to improve usability and mitigate tearing risks. FDA acknowledged these changes, which will be tested in the upcoming HF study.
• Advancement of International Regulatory Submissions: The company is also advancing regulatory submissions for Anaphylm in Canada and the European Union.
• Potential First-in-Class Product: Anaphylm could become the first and only FDA-approved, non-invasive, orally delivered epinephrine product for severe allergic reactions, including anaphylaxis.
• Details on Anaphylm’s Formulation and Packaging: Anaphylm is a polymer matrix-based epinephrine prodrug, similar in size to a postage stamp, begins to dissolve on contact, does not require water or swallowing, and comes in packaging smaller than a credit card, designed for portability and resilience against weather.

Shareholder and Price Sensitive Information

• FDA Feedback and Alignment: Alignment with the FDA on study designs and labeling reduces regulatory risk and increases the likelihood of a successful NDA resubmission and future approval. This is significant for investors as regulatory progress often drives share price movements.
• Timing of NDA Resubmission: Confirmation that the NDA will be resubmitted in Q3 2026 provides a clear timeline for investors to anticipate potential milestones and news flow, which can impact share value.
• Potential Market Opportunity: If approved, Anaphylm would be the only oral epinephrine rescue medication in the market, offering a unique value proposition. This exclusivity could lead to significant commercial potential and impact the company’s valuation.
• International Expansion: Regulatory submissions in Canada and the EU suggest a strategy for global market penetration, which could further boost revenue opportunities and shareholder value.
• Risks and Uncertainties: The company highlights risks including potential delays in regulatory approval, FDA feedback on study designs, manufacturing capabilities, and competition. Investors should monitor regulatory updates closely, as any negative news or delays could adversely affect the share price.
• Financial Obligations and Liquidity: Aquestive notes obligations under Purchase and Royalty Rights Agreements, debt repayments starting in 2026, and reliance on manufacturing revenues. These financial factors may affect the company’s ability to fund ongoing development and commercialization efforts.
• Forward-Looking Statements: All statements about future regulatory approvals, product commercialization, and financial performance are subject to risks and uncertainties, as detailed in the company’s SEC filings.

Company Commentary

Daniel Barber, President and CEO: “The Type A Meeting with FDA confirmed our approach on several key program elements, and we are grateful to the Agency for the productive dialogue on the next steps for our Anaphylm program. We are already hard at work preparing for our human factors and PK studies in support of our planned Anaphylm NDA resubmission in the third quarter of this year. We continue to believe Anaphylm, the first and only oral epinephrine rescue medication, has the potential to be transformative for those at risk of life-threatening allergic reactions. Our commitment to address the long-unmet needs of this community remains strong.”

Additional Developments

• AdrenaVerse™ Platform: Aquestive’s AdrenaVerse platform includes a library of over 20 epinephrine prodrugs targeting allergy and dermatological indications. The company is also developing AQST-108 (epinephrine prodrug) topical gel for conditions such as alopecia areata.
• Manufacturing and Commercialization: The company is the exclusive manufacturer of four commercialized products marketed by licensees across six continents. Manufacturing capabilities and successful commercialization will be critical for future growth.
• Risk Factors Highlighted: Risks include regulatory delays, manufacturing capacity, competition, intellectual property protection, financial obligations, and broader economic uncertainties.

Investor Contact

For further information, investors can contact Brian Korb at astr partners ([email protected]).

Conclusion

The completion of the FDA Type A meeting and reaffirmation of the NDA resubmission timeline represent significant progress for Aquestive Therapeutics. The company’s alignment with the FDA on study designs and labeling language, improvements in product packaging, and plans for international regulatory submissions position Anaphylm as a potentially first-in-class product for severe allergic reactions. These developments are price sensitive and could materially affect the share value depending on the outcome of the regulatory process, commercial launch, and market acceptance. Investors should monitor future announcements, particularly the receipt of final FDA meeting minutes and the NDA resubmission in Q3 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as described in the company’s SEC filings. Investors should conduct their own due diligence and consult their financial advisors prior to making any investment decisions.

View Aquestive Therapeutics, Inc. Historical chart here